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Implications for nursing care 
Management of a DKA patient with severe metabolic and ketoacidosis with chronic renal insufficiency 
Brian Albany BSN, CCRN 
Introduction Case Study References Underlying 
Pathophysiology  
     Diabetic ketoacidosis (DKA) 
serves as one the leading causes of 
mortality in diabetic patients [14]. 
The mortality has decreased over 
the past several decades due to the 
rapid recognition of the disease 
state and the improvement of 
management of DKA [14]. Despite a 
decline in mortality rates over the 
past twenty years from 7.96% to 
0.67%, errors in management of the 
disease state are associated with 
significant morbidity and mortality 
[2]. Utilization of DKA protocols in 
the acute care setting have allowed 
congruency in care and delivery of 
effective lifesaving treatment. 
Despite advances in standardized 
DKA protocols, there still remains a 
gap in how to manage specific 
patient populations with end stage 
renal disease. Understanding the 
pathophysiology behind these 
patient populations will yield better 
outcomes with the ultimate goal of 
decreasing the mortality rate.    
       DKA develops as a result deficient 
levels of insulin circulating throughout the 
body causing a triad of  hyperglycemia, 
hyperketonemia, and acidosis [10,14]. 
Counterregulatory hormones consisted of 
catecholamines, glucagon, and cortisol are 
activated in a state of insulin deficiency 
ultimately causing an increased blood 
glucose level. The glucagon activates 
gluconeogenesis in the liver to form more 
glucose and the body starts to break down 
adipose tissue through lipolysis which 
yields free fatty acids and a state of 
hyperketonemia. The circulating ketones 
induces a state of acidosis with a 
decreased bicarbonate reserve. Severe 
dehydration and electrolyte abnormalities 
occur as the result of osmotic diuresis 
associated with the hyperglycemic state 
[10].     
       Patients with chronic kidney disease 
often develop a common complication of 
metabolic acidosis [3,7]. A state of ph 
homeostasis is usually maintained by the 
functional units of the kidneys or nephrons 
through the excretion of ammonia with a 
normal glomerular filtration rate (GFR). 
When the GFR reaches a dysfunctional 
state of below 40ml/min, there is a 
decrease in ammonium excretion and an 
increase in hydrogen ion retention causing 
a state of acidosis [3]. Other key factors 
that contribute to the acidosis are the 
decreased synthesis of the acid buffer 
bicarbonate and the increased excretion of 
the bicarbonate through the 
gastrointestinal and urinary tract [7].    
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      The current standardized 
DKA protocols do not address 
patients with renal insufficiency. 
Treatment for diabetic patients 
in DKA with chronic kidney 
disease should revolve around 
correcting extreme metabolic 
acidosis states (pH<6.9) before 
the administration of parental 
insulin. This approach will 
increase insulin sensitivity and 
utilization to decrease blood 
glucose levels and halt the 
process of lipolysis, ultimately 
resolving DKA.  
Conclusion 
• Identify if the patient with DKA has 
renal insufficiency 
• Draw serial labs: Chem 7, Beta 
hydroxybutyrate, and ABGs q 6 
hours  
• Consult with physician to obtain 
order to administer sodium 
bicarbonate if pH<6.9 
• Monitor hourly blood glucose level  
• Follow DKA protocol for fluid 
management strategy    
• Provide electrolyte 
supplementation as blood glucose 
levels normalize 
• Call physician to transition patient 
onto subcutaneous insulin when 
anion gap closes  
      A 55 year old female patient with a 
past medical history of type one 
diabetes and end-stage renal disease 
presents to the intensive care unit with 
diabetic ketoacidosis. The patient had 
the following lab values: 
 
• Glucose-1,107 mg/dL 
• Beta hydroxybutyrate-7.6 
mg/dL 
• Anion Gap-36 mEq/l 
• Creatinine-4.54 mg/dL 
• BUN-80 mg/dL 
• GFR-<5ml/min 




• Co2-12 mmHg 
• HCO3-1.9 mmol/L 
• PO2-197 mmHg 
  
      These lab values indicate the 
combination of severe ketoacidosis from 
DKA and metabolic acidosis related to 
chronic renal insufficiency.    
     The patient arrives to the intensive 
care unit with an intact neurological 
status, stable vital signs, and on room 
air. The nurse titrated the insulin drip 
per hospital’s DKA policy. This policy 
states that the nurse is able to double 
the insulin infusion rate if the blood 
glucose level has not decreased after 
initiating the drip. The patient’s blood 
glucose had not improved despite 
intravenous IV insulin; therefore, the 
nurse titrated the drip up to 100 
units/hr. At the same time, the patient 
received 2 amps of sodium bicarbonate 
IV push and was started on a sodium 
bicarbonate infusion. After some time, 
the patient’s labs started to trend in the 
right direction with a closing anion gap, 
decrease in glucose level, increase in pH 
and decrease in ketone levels. The 
insulin infusion rate ran at a rate of 
100units/hr for a total of 5 hours then it 
was weaned off based on the closure of 
the anion gap and decrease in the 
patient’s glucose level.  
     During day shift, the patients’ blood 
glucose plummeted into the low 40s on 
three different occasions. Each time, the 
nurse gave 1 amp of Dextrose 50%.  
 
  
Significance of Pathophysiology 
       Healthcare providers are able to tailor case-specific treatment through an in-
depth analysis and dissection on the pathophysiological processes associated with a 
patient in DKA with a comorbidity of chronic kidney disease. The goal of treatment 
for DKA is to reduce serum glucose levels and ketoacidosis through the 
administration of parental insulin. This will ultimately result in the improvement of 
acidosis and will produce a state of acid-base homeostasis. This may not be an 
effective solution to follow in patients who present with severe metabolic and 
ketoacidosis.  
       Insulin resistance is defined as “a clinical condition where there is a reduced 
biological effect for any given blood concentration of insulin,” [8]. It is characterized 
as reduced tissue responses to the action of insulin [1]. One study concluded that 
there is a direct relationship between a lower serum bicarbonate and high anion 
gap which are both independently associated with reduced insulin sensitivity [4]. 
The data from this study supports the hypothesis that the production of organic 
acid serves as a central feature of insulin resistance [4].  The use of alkali therapy in 
DKA is controversial because the acidosis should correct itself through the 
administration of insulin and fluids; however, many studies show that insulin 
sensitivity is decreased in uremic patients; therefore, treatment of metabolic 
acidosis through alkali therapy is necessary in achieving a decrease in insulin 
resistance with patients that also present with end stage renal disease [1,9,11,13]. 
Data suggests that acidosis should be corrected as soon as possible which will 
result in increased insulin sensitivity to lower blood glucose levels and decrease 
lipolysis [6]. The exogenous insulin given to treat patients in DKA is insensitive and 
ineffective without neutralizing the blood pH through bicarbonate therapy in such 
extreme circumstances. The American Diabetes Association states how severe 
acidosis in hyperglycemic crises can lead to more adverse effects and that adult 
patients with a pH < 6.9 should receive sodium bicarbonate until pH>7.0 is 
achieved [5].   
       The kidneys play a major role in metabolism of insulin [12]. Approximately 
25% of daily insulin production is degraded by the kidneys [12]. Renal metabolism 
is augmented in diabetic patient’s receiving exogenous insulin because the insulin 
bypasses filtration through the liver when injected into the systemic circulation 
[12]. Since the renal clearance of insulin is 200ml/min, patients with an impaired 
GFR will have unfiltered insulin freely circulating in the body [12]. This becomes 
significant when treating a DKA patient with renal insufficiency. Administering 
exogenous IV insulin to this patient without correcting the patient’s acidosis can 
result in serious adverse outcomes and even death by inducing a state of 
hypoglycemia. The patient’s extreme metabolic acidosis will result in a decreased 
insulin sensitivity and a decreased ability to filter insulin out of the body; therefore, 
the patient is at risk for developing hypoglycemia when the acidosis is corrected. 
This concept was evident in the case study when the patient’s blood glucose levels 
had dramatically declined the following day due to increased levels of circulating 
insulin along with the correction of the patient’s acidosis 
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Figure 1: Pathological process of 
DKA [15] 
Figure 2: Three elements of DKA [16] 
